Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: The Oncologist, Oxford University Press (OUP), Vol. 26, No. 10 ( 2021-10-01), p. e1761-e1773
    Abstract: The ACHOCC-19 study was performed to characterize COVID-19 infection in a Colombian oncological population. Methodology Analytical cohort study of patients with cancer and COVID-19 infection in Colombia. From April 1 to October 31, 2020. Demographic and clinical variables related to cancer and COVID-19 infection were collected. The primary outcome was 30-day mortality from all causes. The association between the outcome and the prognostic variables was analyzed using logistic regression models and survival analysis with Cox regression. Results The study included 742 patients; 72% were & gt;51 years. The most prevalent neoplasms were breast (132, 17.77%), colorectal (92, 12.34%), and prostate (81, 10.9%). Two hundred twenty (29.6%) patients were asymptomatic and 96 (26.3%) died. In the bivariate descriptive analysis, higher mortality occurred in patients who were & gt;70 years, patients with lung cancer, ≥2 comorbidities, former smokers, receiving antibiotics, corticosteroids, and anticoagulants, residents of rural areas, low socioeconomic status, and increased acute-phase reactants. In the logistic regression analysis, higher mortality was associated with Eastern Cooperative Oncology Group performance status (ECOG PS) 3 (odds ratio [OR] 28.67; 95% confidence interval [CI] , 8.2–99.6); ECOG PS 4 (OR 20.89; 95% CI, 3.36–129.7); two complications from COVID-19 (OR 5.3; 95% CI, 1.50–18.1); and cancer in progression (OR 2.08; 95% CI, 1.01–4.27). In the Cox regression analysis, the statistically significant hazard ratios (HR) were metastatic disease (HR 1.58; 95% CI, 1.16–2.16), cancer in progression (HR 1.08; 95% CI, 1.24–2.61) cancer in partial response (HR 0.31; 95% CI, 0.11–0.88), use of steroids (HR 1.44; 95% CI, 1.01–2.06), and use of antibiotics (HR 2.11; 95% CI, 1.47–2.95). Conclusion In our study, patients with cancer have higher mortality due to COVID-19 infection if they have active cancer, metastatic or progressive cancer, ECOG PS & gt;2, and low socioeconomic status. Implications for Practice This study's findings raise the need to carefully evaluate patients with metastatic cancer, in progression, and with impaired Eastern Cooperative Oncology Group status to define the relevance of cancer treatment during the pandemic, consider the risk/benefit of the interventions, and establish clear and complete communication with the patients and their families about the risk of complications. There is also the importance of offering additional support to patients with low income and residence in rural areas so that they can have more support during cancer treatment.
    Type of Medium: Online Resource
    ISSN: 1083-7159 , 1549-490X
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2021
    detail.hit.zdb_id: 2023829-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 23, No. 23_Supplement ( 2017-12-01), p. 03-03
    Abstract: Background: HPV-positive head and neck tumors (HNT) correspond to a unique entity given their clinical behavior and molecular characteristics. These tumors can show distinct features on pretreatment imaging, such as well-defined borders and cystic nodal metastases; therefore, the aim of our study was to evaluate the imaging characteristics and determine if there are differences between HPV-positive and HPV-negative HNT tumors in patients studied at our institution. Design: A retrospective pretreatment imaging review from 35 HNT cases recruited under INTERCHANGE- IARC project in Latin America between 11-2014 and 12-2016 was performed. Imaging evaluation included primary lesion and nodal metastases. Initial evaluation by radiologists was blinded for patients' histological findings and HPV status. Radiology was evaluated for: location, tumor size, tumor border morphology, contrast enhancement, nodal metastases, size of metastasis and morphology of nodal metastasis. Radiological findings were correlated with histology and p16 INK4a inmunohistochemistry using clone E6H4 (HPV surrogate marker). Results: Pretreatment images were available for review only in 17 of 35 cases (48,5%). 10 cases had computerized tomography (CT) examination, 1 case magnetic resonance (MR) and 6 cases had 18F-FDG PET-CT. 6/17 cases (35.3%) were excluded due to no visualization of the primary tumor or due to limitation artifacts (amalgam). From the 11 cases available for review, 7 were from the oropharynx (OP), 2 from the oral cavity (OC) and 1 from the larynx (LA). All OP tumors were positive for p16 and all the rest tumors were p16 negative. Tumor size ranged from 7 to 51 mm in greatest dimension. Well-defined borders were present in 4/7 p16 positive tumors vs 2/4 p16 negative tumors. Tumor enhancement with contrast was present and able to evaluate only in 5 out of 11 tumors (3 p16 + and 2 p16 -). All the OP p16 positive tumors presented with nodal metastasis greater than 10 mm in dimension. 6/7 had nodal cystic change and these p16 positive cases were more likely to have large cystic nodal metastases with a cystic component larger than 50% of the nodal size (6/7) than p16/HPV negative tumors (1 out of 4 cases had smaller nodal metastasis with cystic component & lt;50%). Conclusion: Large nodal metastasis ( & gt;10 mm) with cystic component larger than 50% of the node size is an important finding seen in p16 HNT. One should consider these findings when examining neck images in patients with unknown primary in order to exclude malignancy given that usually cystic nodes could be misdiagnosed as benign. Our nondiagnostic imaging rate pretreatment was 35%; in order to improve the use of diagnostic tools we recommend the use of MR especially in patients with amalgams and/or tumor located at the oral cavity and oropharynx. Further studies are granted with a larger sample size in order to validate and confirm imaging characteristics in p16/HPV positive HNT. Citation Format: Nicolás Useche, Oscar Torres, Maria M. Rojas, Mauricio Palau-Lázaro, Marcela Mejía-Arango, Ana Margarita Baldión, José A. Hakim, Johanna Campos, Alberto Escallon, Aylen Vanessa Ospina, Sandra Perdomo, Paula A. Rodríguez-Urrego. Imaging characteristics of head and neck tumors according to human papillomavirus (HPV) status in Bogotá, Colombia [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; April 23-25, 2017; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(23_Suppl):Abstract nr 03.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2017
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2020
    In:  Journal of Clinical Oncology Vol. 38, No. 15_suppl ( 2020-05-20), p. e19259-e19259
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 15_suppl ( 2020-05-20), p. e19259-e19259
    Abstract: e19259 Background: Soft Tissue Sarcomas (STS) are a group of neoplasm with huge histological diversity and biological behaviors. They have a low prevalence and lack of data, especially in Colombia where there is no specific report of this disease. The objective of this study is to describe clinical characteristics and outcomes of patients with soft tissue sarcoma at Fundación Santafe, a university hospital located in Bogotá. Methods: This is an observational study of a cohort of soft tissue sarcoma patients treated at a single institution with a follow-up of 4 years (2015 - 2019). Clinical, molecular and epidemiological variables were registered, and overall survival was calculated for stage IV sarcomas. For the survival analysis a Kaplan Meier model was used. Results: Twenty-four patients were included. The histologies reported were: Pleomorphic sarcoma 25.0%, Ewing's sarcoma 20.8%, liposarcoma 16.7%, chondrosarcoma 8.3%, leiomiosarcoma 8.3%, synovial sarcoma 8.3%, soft part alveolar sarcoma 8.3%, and dermatofibrosarcoma protuberans 4.3%. OSm for the whole stage IV group was: 30.22m, according to subtypes OSm was: Ewing's sarcoma 37.13 OSm, liposarcoma 11 OSm, chondrosarcoma 12.3 OSm. Only 3 of the cases (2 Ewing's sarcoma and 1 alveolar sarcoma) had multigenic platform information. In these cases, main mutations in BCL2, SOX9, SATB2 and TFE3 were described. In two of the cases PDL1 expression was done with a negative result ( 〈 1%) (pleomorphic sarcoma and Ewing's sarcoma). Ifosfamide and anthracyclines was the most frequent chemotherapy regimen used, but in two of the cases checkpoint inhibitors were initiated. Conclusions: This real-world cohort of STS have a similar clinical and epidemiological distribution to historic cohorts, but our OSm for Ewing's sarcoma stage IV is longer than reported, even with a case of complete remission after consolidation with autologous bone marrow transplant. Other histologies had a worse prognosis with a less than 12 m OSm. Genomic data were scarce and useless for directed therapies or immunotherapy as usual in STS. [Table: see text]
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2020
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, No. 16_suppl ( 2022-06-01), p. e18721-e18721
    Abstract: e18721 Background: In our experience during the first year of development of ACHOC-C19 study, we observed 26% mortality in patients with cancer and COVID 19 infection. The impact of vaccination was not evaluated prior to the implementation of this strategy worldwide in this kind of population. It was proposed to evaluate the effectiveness of immunization during the second phase of our investigation. Methods: Cohort study derived from the National Registry of Patients with Cancer and COVID-19 (ACHOCC-19). Data were collected from June 2021 since vaccine was available. Patients were: older than 18 years, diagnosed with cancer (solid tumors), treated and/or under follow-up, and with COVID-19 infection. The comparative analysis of the vaccinated and non-vaccinated cohort is presented. Outcomes included: all-cause mortality within 30 days of infection diagnosis, hospitalization, and mechanical ventilation. Effect estimation was performed through relative risk (RR) and multivariate analysis for each event, using generalized linear models of the binomial family. Results: 896 patients were included, 470 were older than 60 years (52.4%) and 59% women (n = 530). 172 patients were recruited in the vaccinated cohort and 724 in the non-vaccinated cohort (ratio: 1 to 4.2). The cumulative incidence of hospitalization among the unvaccinated was 42.4% (n = 307), and among the vaccinated, 29% (n = 50); invasive mechanical ventilation requirement was 8.4% (n = 61) in unvaccinated, and 4.6% (n = 8) in vaccinated. The cumulative incidence of mortality from all causes in the unvaccinated was 17% (n = 123) and in the vaccinated 4.65% (n = 8). Table summarizes the multivariate analysis. The adjusted RR for mortality for the unvaccinated is 3.4 (95% CI: 1.7-6.8), for hospitalization 1.36 (95% CI: 1.08-1.72), and for mechanical ventilation 2.1 (95% CI: 1.02-4.2). Conclusions: The incidence of complications and death in patients with cancer and COVID-19 infection is significantly higher in those who have not received a vaccination schedule compared to those who have been vaccinated. Immunization should be promoted and intensified in this population group.[Table: see text]
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2022
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Revista Colombiana de Cancerología, Instituto Nacional de Cancerologia, Vol. 25, No. 4 ( 2021-12-23), p. 196-205
    Abstract: Introducción: El melanoma ocasiona el 75% de las muertes por cáncer de piel. Según GLOBOCAN, en 2018 se presentaron 287.723 casos nuevos de melanoma, con una mortalidad de 60.712 casos, que equivale al 20%  de los casos incidentes. Las alternativas para el tratamiento del melanoma, se fundamentan en la estatificación de la enfermedad, y en las características moleculares de la enfermedad. Objetivo: Estructurar un consenso por común acuerdo de expertos, sugerencias para el diagnóstico y tratamiento del melanoma precoz, en el contexto colombiano. Métodos: Se llevó a cabo un consenso de expertos multidisciplinario, constituido por 19 oncólogos clínicos, 2 cirujanos de mama y tejidos blandos, 2 dermatólogos, 2 patólogos y 2 radioterapeutas, miembros activos de la Asociación Colombiana de Hemato Oncología (ACHO). Este consenso se realizó en 4 etapas: 1. Estructuración de 30 preguntas, que se calificaron de 1 a 9, 2. Reenvío de las preguntas no consensuadas, 3. Análisis y discusión de las respuestas y 4. las respuestas no consensuadas se llevaron a un consenso nominal. Resultados: Se discutieron 29 preguntas de diagnóstico y tratamiento de melanoma temprano, se construyeron sugerencias basadas en evidencia utilizada por expertos y guías de manejo de oncología reconocidas internacionalmente adaptadas al contexto y realidad colombiana. Conclusiones: Se presentan sugerencias multidisciplinarias para el diagnóstico y tratamiento de melanoma temprano, las cuales debe considerarse para orientar la toma decisiones y homogeizar la práctica clínica según el contexto colombiano y a las características del sistema de salud colombiano. Este es un documento académico y no regulatorio.
    Type of Medium: Online Resource
    ISSN: 2346-0199 , 0123-9015
    Language: Unknown
    Publisher: Instituto Nacional de Cancerologia
    Publication Date: 2021
    detail.hit.zdb_id: 2584969-4
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Revista Colombiana de Hematología y Oncología, Asociacion Colombiana de Hematologia y Oncologia, Vol. 5, No. 1 ( 2018-07-01), p. 61-71
    Abstract: Introducción: el cáncer de pulmón (CP) es la causa más frecuente de muertes por patologías oncológicas en el mundo1, reportando tasas de incidencia para ambos sexos de 23,1 casos por cada 100 mil habitantes y una mortalidad del 19,4%, según Globocan 20122. Objetivo: consensuar por común acuerdo de expertos recomendaciones para el manejo del cáncer de pulmón metastásico (estadio IV) de célula no pequeña en el contexto colombiano. Métodos: se estructuró un consenso de expertos constituido por 17 oncólogos clínicos, miembros activos de la Asociación Colombiana de Hematología y Oncología (ACHO), que laboran en las principales instituciones del país. Se llevó a cabo en cuatro fases: en la primera fase, se definieron 22 preguntas, las cuales fueron calificadas de 1 a 9; en la segunda, se reenviaron de nuevo las preguntas no consensuadas; en la tercera, se analizaron y discutieron las respuestas; y las no consensuadas fueron a una cuarta fase, donde se hizo un consenso nominal. Resultados: se evaluaron y discutieron 25 preguntas relacionadas con el tratamiento de cáncer de pulmón metastásico (estadio IV) de célula no pequeña y se concluyeron recomendaciones basadas en la mejor evidencia científica y en guías de manejo de oncología reconocidas internacionalmente adaptadas al contexto y realidad colombiana. Conclusiones: se deben considerar los tratamientos para el cáncer de pulmón avanzado según la mejor evidencia científica y la disponibilidad en Colombia, con el fin de ofrecer el mejor tratamiento al paciente. Este consenso es una herramienta para orientar la toma de decisiones clínicas y es útil como documento soporte para consultas de entes públicos y privados. Es importante mencionar que este es un texto académico-científico y no regulatorio.
    Type of Medium: Online Resource
    ISSN: 2256-2915 , 2256-2877
    URL: Issue
    Language: Unknown
    Publisher: Asociacion Colombiana de Hematologia y Oncologia
    Publication Date: 2018
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Asociacion Colombiana de Hematologia y Oncologia ; 2017
    In:  Revista Colombiana de Hematología y Oncología Vol. 4, No. 2 ( 2017-12-01), p. 30-
    In: Revista Colombiana de Hematología y Oncología, Asociacion Colombiana de Hematologia y Oncologia, Vol. 4, No. 2 ( 2017-12-01), p. 30-
    Abstract: Introducción y objetivos. Describir las características demográficas e histopatológicas de pacientes con cáncer colorrectal metastásico que recibieron quimioterapia en CJO entre 2008 y 2011, tratamientos recibidos, posibilidad de metastasectomía, toxicidad y tasas de sobrevida global y libre de progresión.
    Type of Medium: Online Resource
    ISSN: 2256-2915 , 2256-2877
    URL: Issue
    Language: Unknown
    Publisher: Asociacion Colombiana de Hematologia y Oncologia
    Publication Date: 2017
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Revista Colombiana de Hematología y Oncología, Asociacion Colombiana de Hematologia y Oncologia, Vol. 6, No. 2 ( 2019-10-01), p. 10-22
    Abstract: Introducción: el cáncer de pulmón representa una de las patologías oncológicas más frecuentes, con una incidencia del 11,6% y una mortalidad del 18,4%1,2. Durante los últimos años han surgido nuevas tecnologías en el tratamiento de este tipo de cáncer que han impactado positivamente la supervivencia de los pacientes3 . Como alternativa a una guía de práctica clínica, los consensos de expertos son una herramienta para generar documentos a fin de orientar y unificar la práctica médica. Métodos: se llevó a cabo el segundo consenso formal de expertos constituido por 17 oncólogos de la Asociación Colombiana de Hematología y Oncología de las principales ciudades e instituciones del país. Se realizó en cuatro momentos: donde se calificaron preguntas estructuradas por el grupo desarrollador que al final fueron consensuadas en una reunión presencial (nominal). Resultados: se construyeron y calificaron 35 preguntas sobre el tratamiento del cáncer de pulmón metastásico (estadio IV), con sus respectivas sugerencias basadas en la experticia y evidencia disponible reconocidas nacional e internacionalmente, teniendo en cuenta el contexto y regulación del sistema de salud colombiano.
    Type of Medium: Online Resource
    ISSN: 2256-2915 , 2256-2877
    URL: Issue
    Language: Unknown
    Publisher: Asociacion Colombiana de Hematologia y Oncologia
    Publication Date: 2019
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. 12094-12094
    Abstract: 12094 Background: Survivors patients with cancer may suffer long-term consequences related to antineoplastic treatments and tumor itself, leading to deterioration of quality of life and resulting in disturbances including sexual dysfunction (SD). We aimed to identify and characterize SD in a cohort of Spanish patients. Methods: Analytical observational study in patients included in the CLARIFY H2020 project at the Hospital Universitario Puerta de Hierro. From October 2020 to May 2022, clinical and demographic variables were collected as well as measures of sexual function using a validated Spanish-language, gender-targeted separately questionnaire. A descriptive domain on frequency of sexual activity during the last four weeks (DFSA) and multiple domains assessing phases of sexual response (DESR), according to DSM IV and DSM V parameters including desire, arousal, lubrication, orgasm, satisfaction with sexual performance, global sexual satisfaction, anticipatory anxiety and sexual initiative were evaluated. Descriptive, trend associations and logistic regression analyses were performed. Results: 383 patients were included, cancer type distribution was breast cancer 68.14% (261), lung cancer 26.37% (101) and lymphomas 5.50% (21). The average age was 56.5 years (range 33-88). 19.58% (75) of patients were men and 80.42% (308) woman. 69% of men and 31% of women reported they were sexually active. The absolute frequency of Global sexual dissatisfaction (GSD) was 76% in women and 24% in men, according to neoplasia; GSD was 36% in patients with early breast cancer, 14% in men with lymphoma, and 9% in men with lung cancer. Women with metastatic breast cancer presented the highest tendency to have severe disorders of DESR. In multinomial logistic regression, significant associations were found in women with metastatic breast cancer and severe disorders of: arousal (p 0.000), lubrication (p 0.002) orgasm (p 0.000), as well as dissatisfaction with sexual performance (p 0.000) and global sexual dissatisfaction (p 0.000). On the other hand, in women with lung cancer, severe arousal disorder (p 0.016) and global sexual dissatisfaction (p 0.044) were observed. Table. Conclusions: In our study, cancer survivors have high prevalence of SD related with oncological treatment and clinical characteristics of malignancy, being women the most affected population. Efforts should be made to support SD during follow-up to improve the quality of life of this growing oncologic population. [Table: see text]
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, No. 15_suppl ( 2021-05-20), p. e18761-e18761
    Abstract: e18761 Background: Cancer has been described as a risk factor for worse prognosis in people with Covid-19. However, there are few studies informing on the characteristics of cancer patients that have asymptomatic SARS-cov2 infection. The ACHOCC-19 study included asymptomatic patients. Methods: Analytical cohort study of patients with cancer and SARS-cov2 infection in Colombia. From April 1 to October 31, 2020, we collected data on demographic and clinical variables related to cancer and COVID-19 infection. We describe the characteristics and outcomes of patients who had no symptoms of COVID19. Association between outcomes and prognostic variables was analyzed using logistic regression models. Results: We included 742 patients, of which 205 (27.6%) were asymptomatic. Of these 62.2% were older than 61 years, 66% were women, 1.42% were smokers. The most frequent malignancy was breast cancer (25%), followed by colon-rectum (14.6%), sarcoma/soft tissues (5.66%) and lung cancer (5.19%). Patients were more likely to be asymptomatic if they had fewer comorbidities (0-1 comorbidities: 84% asymptomatic, 2 comorbidities: 10.85%, more than 2 comorbidities: 5.15%). 90.5% lived in urban areas and 53.37% had low income. 35.4% of patients had metastatic disease, 8.7% had progressive cancer, 40% had stable disease or partial response. No patient had an ECOG PS of 4 or more, and only 1.91% had ECOG 3. In logistic regression analysis statistically significant associations for having symptomatic disease included: man, presence of 1, 2 or 〉 2 comorbidities, ECOG 1,2 or 3 and cancer in progression. On the other hand, the statistically significant ORs for having asymptomatic disease were age between 18 and 30 years old, cancer in remission and receiving non-cytotoxic treatment. Table sumarizes ORs and their respective 95% CIs of the variables adjusted in the logistic regression model. Conclusions: In our stumdy, cancer patients had a higher probability of asymptomatic COVID-19 infection if they were women, between the ages of 18 and 30 years, had cancer in remission , ECOG 0 and no comorbidities. This is the first cohort of patients with cancer and asymptomatic covid 19 with a significant sample size in Latin America.[Table: see text]
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2021
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages